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Background: A previous theoretic model (Tumour Biol 2013;34:1–7.) that breast tumor
types differ in the relative rate of tissue invasion was elaborated and developed on a
consecutive case series.
Method: Histologic data of 68 ductal breast cancer in situ (DCIS) and 1180 invasive
ductal cancer (IDC) patients were collected and analyzed.
Results: ER+PgR− phenotype was more common in Luminal B2 than among the
pooled Luminal A&B1 (p = 0.0002), and more frequent in Luminal B1 than in Luminal A
(p = 0.0167). The same phenotype was associated with the age older than 54 years in
Luminal B1 and in B2 patients. HER2 type cancers were more frequent in older patients
(p = 0.0038).
Tumor progression from DCIS to IDC was found 39% faster than the average in Luminal
B1 tumors, supporting the clinical importance of this tumor type. A rare combination of
low Ki-67 in HER2 type cancers (only 14% of HER2 type cancers) showed very slow
transition to IDC (occurring at only 53.55% of average progression rate), while
triple-negative cancers progressed faster than the average, despite Ki-67 value (104.63%
for low and 114.27% for high Ki-67 tumors).
In three tumor types with positive steroid receptors the ER+PgR− phenotype showed
slower IDC transition than the ER+PgR+ phenotype of the same tumor type (difference
in progression rate was 38% for Luminal A, 46% for Luminal B1 and 67% for Luminal B2
with Ki67 > 14%).
Triple-negative tumors in younger patients exceeded the expected average progression
rate by 24%, while in HER2 type tumors, the rate of tissue invasion was in younger
patients 20% lower than the expected value.
Conclusions: The relative rate of tissue invasion differed substantialy among our
patients. Differences depended on tumor types, steroid expression phenotypes and
age. The dysfunctional ERs in the ER+PgR− phenotype showed slower rates of tissue
invasion, suggesting that ligand binding to functional breast tumor ERs, beside
promoting the PgR expression, possibly also promotes tumor transition to the invasive
phase.
In triple-negative tumors, an age dependent premenopausal mechanism possibly acted
as an accelerator of tissue invasion, while faster tissue invasion by HER2-overexpressed
tumors in older patients possibly depended on an unidentified mechanism that takes
more time to be acquired, so it was less present in premenopausal patients.© 2014 Kurbel et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Kurbel et al. Theoretical Biology and Medical Modelling 2014, 11:29 Page 2 of 12
http://www.tbiomed.com/content/11/1/29Introduction
Ductal breast cancer in situ (DCIS) seems to precede invasive ductal cancer (IDC). This
idea is based on a high degree of similarity between molecular alterations in DCIS and
invasive cancer in the same patient [1,2], although triple-negative invasive cancers may
seem almost to lack their triple-negative DCIS precursor [3-6].
If all breast cancer types evolve from DCIS lesions, more aggressive breast
cancer types can be recognized by comparing breast tumor type distributions
between DCIS lesions and invasive breast cancers [1]. The basic idea is that at the
time of breast tumor diagnosis more aggressive tumor types will have fewer DCIS
lesions in comparison to less aggressive types with more tumors still in the DCIS
phase.
This model, based on reported data of breast cancer characteristics pooled from
several studies, was proposed in a recent theoretic article [1]. Differences in the
incidences of the main breast cancer types (Luminal A, Luminal B, HER2-
overexpressed and the triple-negative tumors) between DCIS and invasive ductal
cancers (IDC) were used to calculate the relative rate of progression from the in situ
stage to invasive form. This calculated value is probably not directly related to the
course of disease. Instead, it was designed as a parameter that defines chances of a
certain tumor to become invasive at the time of diagnoses. In other words, we were
trying to indirectly measure the speed of the critical phase in breast cancer
development.
After becoming invasive, the future growth depends on many factors. For instance,
HER2-overexpressed tumors were found in the theoretic model to be very slow in
tissue invasion [1], although further development of HER2-overexpressed invasive
breast cancers, is well known as aggressive and rapid. Triple-negative tumors showed
in the pooled model the most rapid rate of tissue progression and this finding was
interpreted as a sign of an unrecognized tumor progression mechanism, independent
of steroid receptors or HER2 expression.
Further to investigate the idea that immunohistochemical characteristics of IDC
and of DCIS tumors from a defined single population can help us to describe biology
of breast tumor types, a sufficiently large sample was required of DCIS and IDC
patients with defined tumor types, ER, PgR, HER2 status and other histological
features. The need for all these data comes from reported breast cancer studies
[7-12] that suggested that PgR expression in cells with ER depends on estrogen
exposure during previous days. In other words, ligand binding to functional ERs is
a physiologic prerequisite for PgR expression in breast tumor cells. This clearly
suggests that the three possible positive steroid receptor breast cancer phenotypes
(ER+PgR+, ER+PgR− and the rare ER−PgR+) may be biologically different, particularly
in this early phase of tumor growth, during tissue invasion.
Without a suitably detailed published data set from a single population, the only
solution was to use a single institution experience in diagnosing 68 DCIS and 1180
IDC patients that has already been attained as a part of an ongoing research project
(219-2192382-2426), financed by the Croatian Ministry of Science.
The aim of this study was to apply numeric methods described in the previous theor-
etic paper [1] on real patient data and thus get more reliable answers on the possible
mechanisms underlying the occurrence of breast cancer types.
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Patients
Data used for the model testing were taken from the above mentioned ongoing
research project (219-2192382-2426), approved by the Ethical Committee of Osijek
Medical Faculty as compliant with the Helsinki Declaration, before grant submission
to Croatian Ministry of Science and Education.
In this study 1248 consecutive patients with intraductal and/or ductal invasive breast
cancers (regardless of stage) were included. All patients were diagnosed and treated in
Osijek Clinical Hospital during the time period from January 2004 to December 2012.
All specimens were excisional biopsy specimens, or mastectomy specimens. 68 cases
were DCIS alone. Tumor grade was determined using the Bloom and Richardson grading
scheme [13].
Immunohistochemistry
Each immunostained slide was evaluated for the presence of ER and PgR expression,
HER2 protein overexpression, and Ki-67 proliferation activity. Immunohistochemical
staining was done by standard avidin-biotin method (DAKO LSAB®2 System, HRP)
using 4 μm sections from representative paraffin blocks. Nuclear staining with anti-ER,
PgR, Ki-67 antibodies was done and the percentage of positive cells per 500 tumor cells
was calculated. Importantly, all ER+ and PgR+ cases showed staining in at least 1% of
the DCIS and/or invasive tumor cell nuclei, whereas all ER-negative and PgR-negative
cases showed complete absence of tumor cell staining (but with staining of normal
breast epithelial cell nuclei) [14].
Tumor cells were considered positive for HER2 protein overexpression when more than
10% of the cells showed strong membrane staining (equivalent to a score of 3+ in the
DakoCytomation HercepTest). HER2 2+ result was only positive if confirmed by chromo-
gene in situ hybridization for gene amplification. All immunostains were initially reviewed
and scored by a single pathologist. Hormone receptors were then reviewed and accepted
as negative if 100% of cells lacked nuclear immunostaining for hormone receptors.
According to immunohistochemical features, tumors (both DCIS and invasive cancers)
were divided into the following five groups: Luminal A (ER+ and/or PgR+, HER2-negative,
Ki-67 < =14%), Luminal B1 (ER+ and/or PgR+, HER2-negative, Ki-67 > 14%), Luminal B2
(ER+ and/or PgR+, HER2-positive, any Ki-67), HER2 (ER−, PgR−, HER2-positive), and
triple-negative (ER−, PgR−, HER2-negative) [15].
Statistical analysis
Collected data were organized in 2×2 tables and differences from expected frequencies
were checked by χ2 tests.
The relative rate of tissue invasion was calculated from a simple contingency table of
DCIS and IDC data according to tumor types. The probability of tumor progression (p) at
the time of diagnosis for each tumor type was calculated using the following equation:
p ¼ BC
DCIS þ BC
where BC stands for the number of all invasive BCs for that tumor type, while DCIS is
the reported number of DCIS lesions of that type.
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prior the time of diagnosis using the following equation:
t1=2 ¼ log 1−pð Þlog 1=2ð Þ
where p is the calculated probability of progression for that tumor type.
This interval is defined as a time required for 50% of DCIS lesions to become invasive.




where tumor_type_t1/2 is the number of elapsed t1/2 for a certain tumor type and
average_t1/2 is the number of elapsed intervals for all included breast tumors.
The model predictions from the ref. 1 were recalculated for the modeled population
with only 5% of DCIS at the time of diagnosis. This recalculation with a similar share
of DCIS tumors allowed comparison between the model results and here presented
data of our patients.
Results
Table 1 shows distributions of our patients regarding breast tumor type, ER & PgR
expression, HER2 overexpression and age (younger than 55, or older than 54). Since
the estrogen-dependent PgR expression occurs only in cells with functional ERs, the
ER+PgR− tumors are considered expressing “dysfunctional” ERs.
Several comparisons were made and they can be summarized in the following statements:
• Dysfunctional ER+PgR− phenotype was more common in Luminal B2 (38 out of 210
cases) in comparison to the pooled Luminal A&B1 (only 66 out of 743 cases), suggesting
that this combination was more prevalent than expected in our patients (p = 0.0002).
• If Luminal A was compared with B1, high Ki-67 values in B1 are also more often
combined with the ER+PgR− phenotype (40 out of 346 vs. 26 out of 397 cases,
p = 0.0167). Thus, tumors with either HER2 overexpression, or with increased Ki-67
values seemed prone to develop the dysfunctional ER+PgR− phenotype.
• Age distributions were similar in the pooled Luminal A&B1 as in B2 (p = 0.1260)
suggesting that age and hormone exposure did not matter much in the tumor type
differentiation between these two types.
• If Luminal B2 tumors are divided according to Ki-67 value and steroid receptor
phenotypes, no important differences were observed (p = 0.5489), suggesting that
distribution of steroid phenotypes and Ki-67 values remain unaltered in tumors
with HER2 overexpression.
• On the other hand, patients’ age was not important for distribution of steroid
receptor phenotypes only in Luminal A patients (p = 0.3789). In Luminal B1 patients
34 out of 40 ER+PgR− tumors were detected in patients older than 54 years. Very
similar distribution was observed in Luminal B2 patients with 34 out of 38 found in
patients older than 54 years. A possible conclusion is that the ER+PgR− phenotype is
more common in tumors with high Ki-67 values or with HER2 overexpression,
particularly in older patients.
Table 1 Distributions of patients regarding breast tumor type, ER and PgR expression,
HER2 overexpression and age (younger than 55, or older than 54)
Luminal A
and B1





Distribution of breast cancer patients with positive receptors according to HER2 and age
ER+PgR+ 666 172 838 <55 218 69 287
ER+PgR− 66 38 104 >54 525 141 666
ER−PgR+ 11 0 11 Total 743 210 953
Total 743 210 953
Χ2 (p) 13.70 (0.0002) Χ2(p) 2.34 (0.1260)







Total Luminal B2 Ki-67 < =14% Ki-67 > 14% Total
ER+PgR+ 365 301 666 ER+PgR+ 49 123 172
ER+PgR− 26 40 66 ER+PgR− 9 29 38
ER−PgR+ 6 5 11 ER−PgR+ 0 0 0
Total 397 346 743 Total 58 152 210
Χ2(p) 5.73 (0.0167) Χ2 (p) 0.36 (0.5489)
Distribution of ductal breast cancer patients according to their age and other features
Age of Luminal
A patients
ER+PgR+ ER+PgR− ER−PgR+ Age of HER2
patients
Ki-67 < =14% Ki-67 > 14% Total
<55 99 5 4 <55 3 38 41
>54 266 21 2 >54 16 78 94
Total 365 26 6 Total 19 116 135
Χ2(p) 0.77 (0.3789) Χ2 (p) 2.22 (0.1360)
Age of Luminal
B1 patients
ER+PgR+ ER+PgR− ER−PgR+ Age of triple-
negative patients
Ki-67 < =14% Ki-67 > 14% Total
<55 103 6 1 <55 7 68 75
>54 198 34 4 >54 14 71 85
Total 301 40 5 Total 21 139 160
Χ2(p) 6.00 (0.0143) Χ2 (p) 1.78 (0.1822)
Age of Luminal
B2 patients





<55 65 4 0 <55 75 41 116
>54 107 34 0 >54 85 94 179
Total 172 38 0 Total 160 135 295
Χ2(p) 10.49 (0.0012) Χ2 (p) 8.36 (0.0038)
The ER+PgR- phenotype was more common in Luminal B2 in comparison to the pooled Luminal A and B1, in Luminal B1.
In Luminal B1 and in B2 ER+PgR- tumors were more common in patients older than 54. HER2-overexpressed patients are
often older than 54.
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value and patients’ age did not show any difference, and the same was found for
triple-negative tumors. Nevertheless, if we compare age of HER2 versus triple-
negative patients, HER2 patients are obviously often older than 54 years (94 out of
135 in comparison to 85 out of 160 triple-negative cases, p = 0.0038). This suggests
that HER2 tumors might be slower in the initial growth phase so they were more
often diagnosed in older patients.
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to patients in this study. For the comparison purpose only, data from ref. 1. were recal-
culated to simulate population of breast tumor patients with 5% of DCIS at the time of
diagnosis. The recalculation was evidently well matched since the number of spent T1/2
of progression was very similar in presented data and in the recalculated simulated
population (only above 4 t1/2 are spent in both data sets). Relative rates were calculated
relative to the average progression rate of all tumors (the average count of spent t1/2 for
all BC patients was 4.198), making the relative rates easily comparable:
• The most rapid progression was observed for Luminal B1 cancers and then for













DCIS A 34 6 12 10 6 68
IDC B 363 340 198 125 154 1180
Number of all DC
(A + B)
C 397 346 210 135 160 1248
% of cancer types
in all DC





p 91.44% 98.27% 94.29% 92.59% 96.25% 94.55%
Number of progression
t1/2 spent till the
time of diagnosis
log(1-p)/log(1/2)
3.55 5.85 4.13 3.75 4.74 4.20
Relative rate of
progression
from DCIS to IDC
84.46% 139.35% 98.36% 89.45% 112.84% 100.00%
Pooled reported
DCIS and IDC data
from ref. 1





DCIS 153 53 96 26 328
IDC 124 68 31 109 332
Total 277 121 127 135 660
Simulated population
of all ductal breast
cancer patients with
5% DCIS
2480.61 1329.43 677.90 2072.05 6560
% of cancer types in
simulated population




93.83% 96.01% 85.84% 98.75% 95.00%
Number of
progression t1/2
spent till the time
of diagnosis
4.02 4.65 2.82 6.32 4.32
The fastest in tissue invasion were Luminal B1 cancers and then the triple-negative cancers. Based on relative rates of
tissue invasion it seems that criteria for Luminal B1 have really identified the most aggressive breast cancers.
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sue progression rate.
As Luminal B1 cancers differ from Luminal A cancers only in Ki-67 values, the same
threshold of 14% Ki-67 value was applied in Table 3 to Luminal B2, HER2-
overexpressed and triple-negative cancers:
• Luminal B1 phenotype exceeded the average progression rate by 39%, supporting
the clinical importance of this phenotype. The Ki-67 subtypes of Luminal B2
(proposed in this study), HER2-overexpressed and triple-negative cancers were not
so impressive.
• Low Ki-67 decreased the rate of Luminal B2 tissue progression (27% of Luminal B2
cancers showed 91.9% of the average progression rate).
• A rare combination of low Ki-67 in HER2-overexpressed cancers (14% of
HER2 cancers) showed very slow rate of tissue invasion (only 53.55% of the
average rate).
• The triple-negative cancers progressed faster than the average rate, despite the Ki-67
value (104.63% for low and 114.27% for high Ki-67).Table 3 Relative tissue invasion rates according to the Ki-67 value
Binary features DCIS IDC Relative rate Rate difference
(positive–negative)
ER Negative 16 290 1.0142 −0.0186
Positive 52 890 0.9955
Total 68 1180 1.0000
PgR Negative 29 370 0.9010 0.1577
Positive 39 810 1.0587
Total 68 1180 1.0000
HER2 Negative 46 857 1.0231 −0.0772
Positive 22 323 0.9459
Total 68 1180 1.0000
Ki-67 <=14% 43 451 0.8390 0.3317
>14 25 729 1.1707
Total 68 1180 1.0000
Ductal breast cancer types
including Luminal B1 and
proposed other Ki-67 subtypes
Luminal A 34 363 0.8446 0.5489
Luminal B1 6 340 1.3936
Luminal B2 <=14% 4 54 0.9190 0.0929
>14% 8 144 1.0119
HER2 <=14% 4 15 0.5355 0.4824
>14% 6 110 1.0179
Triple-negative <=14% 1 20 1.0463 0.0964
>14% 5 134 1.1427
Total 68 1180 1.0000
Because Luminal B1 cancers differ from Luminal A cancers only by Ki-67 values, the same threshold of the 14% Ki-67
value was applied to Luminal B2, HER2-overexpressed and triple-negative cancers. Luminal B1 phenotype was 39% faster
than average in progression. The rare combination of low Ki-67 in HER2-overexpressed cancers (14% of HER2 cancers)
showed very slow rate of transition to IDC (only 53.55% of the average rate).
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expression are shown in Table 4:
• In all three tumor types with positive steroid receptors the ER+PgR− phenotype
showed slower tissue progression rates than the functional ER+PgR+ phenotype (by
38% for Luminal A, 46% for Luminal B1 and 67% for Luminal B2 with Ki67 > 14%),
suggesting that if estrogen binding to dysfunctional ERs did not promote PgR
expression, it also did not stimulate tissue invasion.
Table 5 shows comparison of calculated relative rates of tissue invasion between pa-
tients younger than 55 and older patients:
• The main difference was found in patients with triple-negative tumors whose pro-
gression rate exceeded the expected average rate in younger patients by 24%, while in
older patients it was only 5% above the expected value.
• In HER2-overexpressed tumors, the rate of tissue invasion among older patients was
5% bellow the expected value, but in younger patients the rate was 20% lower than
the expected values.
• All other features, including two steroid receptor phenotypes (ER+PgR+ and ER−PgR−)
were not found to be dependent on age.
These data suggest that tumor biology in two types of ER negative tumors (HER2-
overexpressed and triple-negative tumors) was altered mainly in younger patients. TheTable 4 Relative tumor invasion rates according to the expression of hormonal receptors





ER+PgR+ 39 799 1.0542 −0.3396
ER+PgR− 13 91 0.7146
ER−PgR+ 0 11 n/a
ER−PgR− 16 279 1.0016
Total 68 1180 1.0000
Luminal A cancers: steroid
receptor phenotype
ER+PgR+ 28 337 0.8824 −0.3785
ER+PgR− 6 20 0.5039
ER−PgR+ 0 6 n/a
Total 34 363 0.8446
Luminal B1 cancers: steroid
receptor phenotype
ER+PgR+ 4 297 1.4849 −0.4554
ER+PgR− 2 38 1.0295
ER−PgR+ 0 5 n/a
Total 6 340 1.3934
Luminal B2 cancers: steroid
receptor phenotype
<=14% ER+PgR+ 4 45 0.8606 n/a
ER+PgR− 0 9 n/a
>14% ER+PgR+ 3 120 1.2756 −0.6718
ER+PgR− 5 24 0.6038
Total 12 198 0.9832
In all three tumor types with positive steroid receptors the ER+PgR- phenotype showed slower transition rates to the
IDC phase than the functional ER+PgR+ phenotype ( 38% for Luminal A, 46% for Luminal B1 and 67% for Luminal B2
with Ki67 > 14%).
Table 5 Comparison of calculated relative rates of tissue invasion between patients
younger than 55 vs. older patients
Features Age <55 years Age >54 years Rate difference
(older-younger)DCIS IDC Relative rate DCIS IDC Relative rate
Luminal A 8 100 0.8944 26 263 0.8277 −0.0667
Luminal B1 2 108 1.3772 4 232 1.4013 0.0241
Luminal B2 4 65 0.9787 8 133 0.9861 0.0074
HER2 4 37 0.7998 6 88 0.9456 0.1458
Triple-negative 2 73 1.2456 4 81 1.0504 −0.1952
Total 18 275 0.9588 44 565 0.903 −0.0558
ER+PgR+ 14 253 1.0151 25 546 1.0752 0.0601
ER+PgR− 0 15 n/a 13 76 0.6611 n/a
ER−PgR− 6 110 1.0198 10 169 0.9914 −0.0284
Total 20 378 1.0298 48 791 0.9832 −0.0466
The main difference was found in patients with triple-negative tumors that were in younger patients 24% faster than the
expected average, while in older patients it was only 5% above the expected value. In HER2-overexpressed tumors,
among older patients, the rate of tumor invasion was a just 5% bellow the expected value, but in younger patients the
tissue invasion rate was 20% below the expected values. The ER+ER- phenotype was 33% slower than expected in older
patients and incalculably fast in younger patients with no DCIS found among 15 younger patients.
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slower in younger patients. A possible interpretation regarding HER2-overexpressed
tumors is that invasion in these tumors depends on an as yet unidentified mechanism
that takes more time to be acquired. In triple-negative tumors, some age dependent
mechanism accelerated tissue invasion in younger patients, but it seemed absent after
the menopause. Thus, it is possible that we should be looking for another humoral
factor, possibly related to ovulatory cycles, although not dependent on the presence of
estrogen or progesterone receptors.
Discussion
This study started from a theoretic paper [1] that addressed several questions regarding
tumor invasion into the breast tissue. As shown in previous sections of this paper,
assembling a regionally limited case series of breast cancer patients allowed complex
questions to be addressed.
Several arguments can be drawn from the presented results. Among the pooled
patients’ results from ref. 1, Luminal A was found in near 38% of patients and triple-
negative tumors in almost 32% of patients, Luminal B in 20% and HER2-overexpressed
in 10% of patients. In our study, the share of triple-negative tumors was smaller (near
13%) while the pooled Luminal A & B1 (analogous to Luminal A in ref. 1) were found
in almost 60% of all patients. These differences possibly reflected the improved sensi-
tivity of ER and PgR detection by modern immunohistochemical staining and thus
reduced the proportion of triple-negative cancers (from predicted 32% in simulated
population to only 12.82% found among the presented cases). This suggests that many
tumors among the pooled data from ref. 1., had been classified by the then contempor-
ary immunohistochemical methods as triple-negative, while similar tumors among our
patients possibly often met the criteria for Luminal B1 tumors.
The dysfunctional ER+PgR− phenotype was more common in Luminal B2 in compari-
son to the pooled Luminal A&B1 tumors, and also more frequent in Luminal B1 than
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Ki-67 values were in our patients linked to this phenotype with dysfunctional ERs.
On the other hand, the same ER+PgR− phenotype among the three tumor types with
positive steroid receptors showed slower tissue invasion than the ER+PgR+ phenotype
of the same tumor type (progression rate differences by 38% for Luminal A, 46% for
Luminal B1 and 67% for Luminal B2 with Ki67 > 14%). If the presence of functional
ERs is so important for tissue invasion in several breast tumor types, a plausible ques-
tion is whether the efficacy of conventional hormonal therapy is compromised in
patients with dysfunctional ERs (those patients with the ER+PgR− tumor phenotype).
Tumor progression from DCIS to IDC was found to exceed the average rate by 39%
in Luminal B1 tumors, supporting the clinical importance of this tumor type. A rare
combination of low Ki-67 in HER2 type cancers showed very slow tissue invasion (only
53.55% of the average rate). Triple-negative cancers showed tissue progression rates
above the average, regradless of the Ki-67 value (104.63% for the low and 114.27% for
the high Ki-67 tumors). These findings suggest that high Ki-67 values might be used as
a surrogate marker of an as yet unrecognized invasion promoting mechanisms in breast
tumor types, except among the triple-negative cancers.
When considering age of patients and the relative rate of tissue invasions, breast
tumors with the dysfunctional ER+PgR− phenotype progressed faster in younger
patients and 33% slower than expected in older patients. Triple-negative tumors in
younger patients were 24% faster than the expected average, while in HER2-
overexpressed tumors, the rate of tumor invasion in younger patients was 20% lower
than the expected value. A possible interpretation regarding HER2-overexpressed
tumors is that invasion in these tumors depends on an unidentified mechanism that
takes more time to be acquired. In triple-negative tumors, an age dependent premeno-
pausal mechanism possibly accelerates tissue invasion without binding to ERs or PgRs
(possibly activin/inhibin [16-18] or some other).
Conclusions
A previously developed theoretic model, from the pooled published breast cancer data
[1], suggested that all breast cancer types evolve from DCIS lesions. If so, the more
tissue invasive breast cancer types can be recognized by comparing breast tumor type
distributions between DCIS lesions and invasive breast cancers, through calculation of
the relative rate of tissue invasion.
By using the same approach on a case series from a single institution, the following
complex results were obtained:
• Among our patients, the share of DCIS tumors was only 5.45% of all breast cancer
cases, probably reflecting late detection of breast tumors in our population.
• The fastest tissue invasion was observed among luminal B1 cancers, supporting the
clinical importance of this phenotype and suggesting that the tissue invasion rate of
Luminal B1 tumors depends on high Ki-67 value.
• The subgroup of 301 patients with the ER+PgR+ phenotype of Luminal B1 tumors
showed even a higher rate of tumor invasion. Beside that in all three tumor types
with positive steroid receptors (Luminal A, B1 and B2), the dysfunctional ERs in the
ER+PgR− phenotype showed slower rates of tissue invasion. These results suggest
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expression, possibly also promotes tumor transition to the invasive phase.
• The rare combination of low Ki-67 in HER2-overexpressed cancers (14% of HER2
cancers) showed very slow rate of tissue invasion. This suggests that the phenotype
with low Ki-67 in HER2 type cancers might be recognized as a subgroup that longer
remain in the DCIS phase at the time of diagnosis than any other cancer types.
The tested model was focused on the very early breast tumor growth phase that leads
to tissue invasion, so these results are not necessary important for the subsequent clin-
ical course of invasive ductal cancer. Nevertheless, an investigation into whether the
here described subgroups also show differences in subsequent phases of cancer growth
or in treatment responses seem warranted.
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